These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 21747119)
21. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479 [TBL] [Abstract][Full Text] [Related]
29. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Dullaers M; Van Meirvenne S; Heirman C; Straetman L; Bonehill A; Aerts JL; Thielemans K; Breckpot K Gene Ther; 2006 Apr; 13(7):630-40. PubMed ID: 16355115 [TBL] [Abstract][Full Text] [Related]
30. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide]. Zhang W; He L; Cao X Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032 [TBL] [Abstract][Full Text] [Related]
31. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. Iwata-Kajihara T; Sumimoto H; Kawamura N; Ueda R; Takahashi T; Mizuguchi H; Miyagishi M; Takeda K; Kawakami Y J Immunol; 2011 Jul; 187(1):27-36. PubMed ID: 21632716 [TBL] [Abstract][Full Text] [Related]
32. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330 [TBL] [Abstract][Full Text] [Related]
33. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. Okada N; Iiyama S; Okada Y; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A Cancer Gene Ther; 2005 Jan; 12(1):72-83. PubMed ID: 15389286 [TBL] [Abstract][Full Text] [Related]
34. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Wan Y; Emtage P; Zhu Q; Foley R; Pilon A; Roberts B; Gauldie J Cell Immunol; 1999 Dec; 198(2):131-8. PubMed ID: 10648127 [TBL] [Abstract][Full Text] [Related]
35. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806 [TBL] [Abstract][Full Text] [Related]
36. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
37. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. Liu Y; Huang H; Chen Z; Zong L; Xiang J J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636 [TBL] [Abstract][Full Text] [Related]
38. Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency. Yoshikawa T; Niwa T; Mizuguchi H; Okada N; Nakagawa S Gene Ther; 2008 Oct; 15(19):1321-9. PubMed ID: 18480845 [TBL] [Abstract][Full Text] [Related]
39. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. den Brok MH; Sutmuller RP; Nierkens S; Bennink EJ; Toonen LW; Figdor CG; Ruers TJ; Adema GJ Cancer Res; 2006 Jul; 66(14):7285-92. PubMed ID: 16849578 [TBL] [Abstract][Full Text] [Related]
40. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Pereboev AV; Nagle JM; Shakhmatov MA; Triozzi PL; Matthews QL; Kawakami Y; Curiel DT; Blackwell JL Mol Ther; 2004 May; 9(5):712-20. PubMed ID: 15120332 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]